NEW YORK, NY--(Marketwired - May 6, 2015) - New ads and sales materials, created by Glue Advertising for Meda Pharmaceuticals' seasonal nasal allergy medication Dymista® (azelastine hydrochloride and ...

SAN ANTONIO — Azelastine hydrochloride and fluticasone propionate dual agent nasal spray effectively reduced ocular itch and nasal congestion in patients with seasonal allergic rhinitis, according to ...

Meda announced today positive results from a Phase III clinical trial of Dymista (also known as MP29-02), a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with ...

Meda announced new results from its Phase 3 study of Dymista (azelastine HCl and fluticasone propionate; Meda) nasal spray for the treatment of allergic rhinitis. Data from three randomized, ...

DYMISTA (azelastine and fluticasone propionate) nasal spray by Meda Meda announced that the FDA has approved Dymista (azelastine HCl and fluticasone propionate) nasal spray for the treatment of ...

“These data show support for the safety and efficacy of this novel nasal spray formulation, especially for patients who have persistent symptoms of seasonal allergic rhinitis that may require ...

A nasal spray that claims to treat hay fever twice as fast as existing medication has been launched as pollen levels hit a springtime peak. Dymista spray contains two drugs which work differently to ...

Cipla, on Wednesday, said it had granted the global commercialisation rights for its nasal spray Dymista to Swedish partner Meda AB, except for certain geographies. The two companies said they had ...

Meda presents new positive results from a Phase-III clinical trial of Dymista (also known as MP29-02) at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in ...

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA) presents new positive results from a Phase-III clinical trial of Dymista (also known as MP29-02) at the annual meeting of the ...